Survival outcomes associated with antidepressant use in glioblastoma: a cohort study - Takeaways - MDSpire

Survival outcomes associated with antidepressant use in glioblastoma: a cohort study

  • By

  • Yifei Sun

  • Mohammad Hamo

  • Travis Atchley

  • James M. Markert

  • Burt Nabors

  • Dagoberto Estevez-Ordonez

  • October 27, 2025

  • 0 min

Share

  • 1

    Glioblastoma is the most common primary brain tumor in adults, with a median survival of approximately 15 months despite current treatments.

  • 2

    Depression affects nearly 40% of glioblastoma patients and is linked to poor outcomes, leading to frequent antidepressant prescriptions.

  • 3

    The impact of antidepressants on glioblastoma survival is inconclusive, with studies showing both improved and worsened survival outcomes.

  • 4

    This study aims to evaluate the independent effects of various antidepressant classes on glioblastoma survival, considering socioeconomic and molecular factors.

  • 5

    A retrospective review was conducted on glioblastoma patients treated between 2008 and 2023, analyzing medication records and survival outcomes.

Original Source(s)

Survival outcomes associated with antidepressant use in glioblastoma: a cohort study

  • by Yifei Sun, Mohammad Hamo, Travis Atchley, James M. Markert, Burt Nabors, Dagoberto Estevez-Ordonez

  • October 27, 2025

Related Content

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026

FOXA2 in cancer: from fundamental biology to clinical translation